Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s LY-3972406?
LY-3972406 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris).
LY-3972406 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris).
What's Your Reaction?
